新一代全身数字SPECT/CT在转移性去势抵抗性前列腺癌患者中评估[177Lu]Lu-PSMA-617治疗反应的当日治疗后成像
这项回顾性研究纳入68例接受[177Lu]Lu-PSMA-617治疗的进展性转移性去势抵抗性前列腺癌男性患者,评估新一代CZT SPECT/CT系统在输注后当日(平均1.8±0.6小时)成像的临床效用。56例接受至少2次治疗后SPECT/CT的患者中,37例(66%)Lu-TTV降低>30%,与总生存期(中位未达到 vs 6个月,P=0.008)和无PSA进展生存期(中位6个月 vs 1个月,P<0.001)显著改善相关;SUVmax或SUVmean变化与PSA-PFS或OS无相关性。
要点
- 当日治疗后SPECT/CT(约12分钟/次)耐受良好,221次当日扫描占89%。
- 37例(66%)患者Lu-TTV降低>30%,与OS和PSA-PFS显著改善相关。
- SUVmax或SUVmean变化与PSA-PFS或OS无相关性。
核心结论
- 研究成功实施了[177Lu]Lu-PSMA-617输注后当日SPECT/CT成像。
- 治疗后1-2小时SPECT/CT图像的定量分析是评估治疗反应的有前景方法。
- 该方法目前受限于对小肿瘤病灶检测欠佳以及需要纳入第三周期SPECT/CT以减轻潜在治疗相关 flare-up 的影响。
- 需要在更大患者队列中进一步研究和前瞻性验证以确认这些发现,并探索SPECT/CT作为PSMA PET/CT潜在辅助手段在mCRPC管理中的作用。
研究设计与样本
- 回顾性研究,纳入2022年6月至2023年6月在本中心接受[177Lu]Lu-PSMA-617治疗的68例进展性mCRPC男性患者。
- 输注后行数字全身SPECT/CT成像(平均±SD:1.8±0.6小时,范围1.1-4.9小时)。
- 对接受至少2次治疗后SPECT/CT的患者,以肝实质摄取为参考,对[177Lu]Lu-PSMA-617阳性病灶进行定量分析。
- 计算[177Lu]Lu-PSMA-617阳性总肿瘤体积(Lu-TTV)、SUVmax和SUVmean等指标。
- 将第1、2、3周期后输注后SPECT/CT图像上的这些定量指标与总生存期(OS)、根据前列腺癌工作组3(PCWG3)定义的前列腺特异性抗原进展无生存期(PSA-PFS)以及PSA下降超过50%(PSA50)缓解率进行相关性分析。
主要发现
- 56例患者(平均年龄76.2±8.1岁,范围60-93岁)接受至少2次治疗后SPECT/CT并纳入图像分析。
- 全身SPECT/CT扫描(约12分钟/次)耐受良好,共完成221次当日扫描(89%)。
- 中位随访10个月时,33例(58.9%)患者在[177Lu]Lu-PSMA-617治疗后达到PSA50,中位PSA-PFS为5.0个月(范围1.0-15个月),中位OS未达到。
- SPECT/CT图像定量分析显示,37例(66%)患者Lu-TTV降低>30%,与总生存期显著改善相关(中位未达到 vs 6个月,P=0.008)和PSA-PFS显著改善相关(中位6个月 vs 1个月,P<0.001)。
- SUVmax或SUVmean的变化与PSA-PFS或OS无相关性。
关键数值与推荐
- 以肝实质摄取作为参考进行定量分析。
- PSA-PFS根据PCWG3定义。
- PSA50缓解率定义为PSA下降超过50%。
- Lu-TTV降低>30%与OS和PSA-PFS改善相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该方法目前受限于对小肿瘤病灶检测欠佳。
- 需要纳入第三周期SPECT/CT以减轻任何潜在治疗相关 flare-up 的影响。
- 需要在更大患者队列中进一步研究和前瞻性验证以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lutetium-177 [177Lu]Lu-PSMA-617 radioligand therapy (RLT) represents a significant advancement for metastatic castration-resistant prostate cancer (mCRPC), demonstrating improvements in radiographic progression free survival (rPFS) and overall survival (OS) with a low rate of associated side effects. Currently, most post-therapy SPECT/CT is conducted at 24 h after infusion. This study examines the clinical utility of a next-generation multi-detector Cadmium-Zinc-Telluride (CZT) SPECT/CT system (StarGuide) in same-day post-infusion assessment and early treatment response to [177Lu]Lu-PSMA-617. METHODS: In this retrospective study, 68 men with progressive mCRPC treated with [177Lu]Lu-PSMA-617 at our center from June 2022 to June 2023 were evaluated. Digital whole-body SPECT/CT imaging was performed after [177Lu]Lu-PSMA-617infusion (mean ± SD: 1.8 ± 0.6 h, range 1.1-4.9 h). Quantitative analysis of [177Lu]Lu-PSMA-617 positive lesions was performed in patients who underwent at least 2 post-therapy SPECT/CT, using liver parenchyma uptake as reference. Metrics including [177Lu]Lu-PSMA-617 positive total tumor volume (Lu-TTV), SUVmax and SUVmean were calculated. These quantitative metrics on post-infusion SPECT/CT images after cycles 1, 2 and 3 were correlated with overall survival (OS), prostate specific antigen-progression free survival (PSA-PFS) as defined by prostate cancer working group 3 (PCWG3), and PSA decrease over 50% (PSA50) response rates. RESULTS: 56 patients (means age 76.2 ± 8.1 years, range: 60-93) who underwent at least 2 post-therapy SPECT/CT were included in the image analysis. The whole-body SPECT/CT scans (~ 12 min per scan) were well tolerated, with 221 same-day scans performed (89%). At a median of 10-months follow-up, 33 (58.9%) patients achieved PSA50 after [177Lu]Lu-PSMA-617 treatment and median PSA-PFS was 5.0 months (range: 1.0-15 months) while median OS was not reached. Quantitative analysis of SPECT/CT images showed that 37 patients (66%) had > 30% reduction in Lu-TTV, associated with significantly improved overall survival (median not reached vs. 6 months, P = 0.008) and PSA-PFS (median 6 months vs. 1 months, P < 0.001). However, changes in SUVmax or SUVmean did not correlate with PSA-PFS or OS. CONCLUSION: We successfully implemented same-day post-therapy SPECT/CT after [177Lu]Lu-PSMA-617 infusions. Quantitation of 1-2 h post-therapy SPECT/CT images is a promising method for assessing treatment response. However, the approach is currently limited by its suboptimal detection of small tumor lesions and the necessity of incorporating a third-cycle SPECT/CT to mitigate the effects of any potential treatment-related flare-up. Further investigation in a larger patient cohort and prospective validation is essential to confirm these findings and to explore the role of SPECT/CT as a potential adjunct to PSMA PET/CT in managing mCRPC.
引用
- Song H, Leonio MI, Ferri V, et al. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 38635050. doi:10.1007/s00259-024-06718-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。